Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naveen S Basappa

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Cancer|October 12, 2018
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumSteven M Yip, Connor Wells, Raphael Moreira, et al.
Urologic Oncology|February 26, 2022
Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in CanadaBobby Shayegan, Christopher J D Wallis, Shawn Malone, et al.
European Urology Oncology|December 14, 2023
Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic TherapiesGhady Bou-Nehme Sawaya, Alice Dragomir, Lori A Wood, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 27, 2023
High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experienceHanbo Zhang, Nimira S Alimohamed, Naveen S Basappa, et al.
Cancers|February 13, 2025
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status PatientsNoa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, et al.
Clinical Genitourinary Cancer|April 27, 2025
Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World StudyGhady Bou-Nehme Sawaya, Simon Tanguay, Lori A Wood, et al.
BJUI Compass|August 11, 2022
Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based studyShawn Malone, Christopher J D Wallis, Richard Lee-Ying, et al.
The Journal of Urology|December 27, 2022
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Vishal Navani, Matthew S Ernst, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis DatabaseChangsu Lawrence Park, Feras Ayman Moria, Sunita Ghosh, et al.
The Oncologist|April 17, 2024
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimensEddy Saad, Georges Gebrael, Karl Semaan, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Cancer|October 12, 2018
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumSteven M Yip, Connor Wells, Raphael Moreira, et al.
Urologic Oncology|February 26, 2022
Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in CanadaBobby Shayegan, Christopher J D Wallis, Shawn Malone, et al.
European Urology Oncology|December 14, 2023
Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic TherapiesGhady Bou-Nehme Sawaya, Alice Dragomir, Lori A Wood, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 27, 2023
High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experienceHanbo Zhang, Nimira S Alimohamed, Naveen S Basappa, et al.
Cancers|February 13, 2025
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status PatientsNoa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, et al.
Clinical Genitourinary Cancer|April 27, 2025
Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World StudyGhady Bou-Nehme Sawaya, Simon Tanguay, Lori A Wood, et al.
BJUI Compass|August 11, 2022
Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based studyShawn Malone, Christopher J D Wallis, Richard Lee-Ying, et al.
The Journal of Urology|December 27, 2022
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Vishal Navani, Matthew S Ernst, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis DatabaseChangsu Lawrence Park, Feras Ayman Moria, Sunita Ghosh, et al.
The Oncologist|April 17, 2024
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimensEddy Saad, Georges Gebrael, Karl Semaan, et al.
Pageof 6